Table 2. Baseline characteristics of patients with and without events at follow-up.
| Clinical and laboratory characteristics | Events (n = 57) | No events (n = 38) | P value |
| Age (yr) | 65.9 ± 11.8 | 63.3 ± 12.6 | 0.3 |
| Gender (M/F) | 42/15 | 27/11 | 0.8 |
| Weight (kg) | 78.9 ± 17.1 | 74.5 ± 15.6 | 0.2 |
| NYHA class | I = 1 (1.7) | I = 3 (7.8) | 0.1 |
| II = 29 (50.8) | II = 24 (63.2) | ||
| III = 27 (47.3) | III = 11 (29) | ||
| CAD | 44 (57) | 28 (74) | 0.7 |
| Smoking | 20 (35) | 12 (32) | 0.7 |
| Diabetes | 19 (33) | 12 (32) | 0.9 |
| SBP (mmHg) | 125 ± 17 | 124 ± 13 | 0.7 |
| Haemoglobin (g/dL) | 12.7 ± 2.1 | 13.2 ± 1.7 | 0.2 |
| Lymphocytes (%) | 22.7 ± 7.5 | 22.2 ± 7.3 | 0.7 |
| Total cholesterol (mg/dL) | 163.9 ± 50.8 | 179.7 ± 36.3 | 0.2 |
| Serum uric acid (mg/dL) | 5.7 ± 1.9 | 6.2 ± 1.9 | 0.3 |
| Serum sodium (mEq/L) | 140.4 ± 3.6 | 140.4 ± 2.8 | 0.9 |
| Sinus rhythm | 41 (72) | 29 (76) | 0.6 |
| ICD | 7 (12) | 4 (10.5) | 0.8 |
| Medications | |||
| β-blockers | 42 (74) | 24 (63) | 0.3 |
| ACE-I | 22 (39) | 18 (47) | 0.4 |
| ARB | 19 (33) | 11 (29) | 0.6 |
| Antialdosteronic agents | 9 (16) | 5 (13) | 0.7 |
| Statins | 30 (53) | 23 (61) | 0.4 |
| Allopurinol | 7 (12) | 6 (16) | 0.6 |
| Furosemide (mg/day) | 48.6 ± 94.1 | 29.8 ± 48.4 | 0.3 |
Data are presented as mean ± SD or n (%). ACE-I: Angiotensin converting enzyme-inhibitors; ARB: angiotensin receptor blockers; CAD: coronary artery disease; ICD: implantable cardioverter defibrillator; NYHA: New York Heart Association; SBP: systolic blood pressure; SD: standard deviation.